IN2015DN01786A - - Google Patents

Info

Publication number
IN2015DN01786A
IN2015DN01786A IN1786DEN2015A IN2015DN01786A IN 2015DN01786 A IN2015DN01786 A IN 2015DN01786A IN 1786DEN2015 A IN1786DEN2015 A IN 1786DEN2015A IN 2015DN01786 A IN2015DN01786 A IN 2015DN01786A
Authority
IN
India
Prior art keywords
subject
pronucleotide
administering
formula
need
Prior art date
Application number
Other languages
English (en)
Inventor
P Iyer Radhakrishnan
Padmanabhan Seetharamaiyer
Original Assignee
Spring Bank
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spring Bank filed Critical Spring Bank
Publication of IN2015DN01786A publication Critical patent/IN2015DN01786A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
IN1786DEN2015 2005-12-13 2006-12-13 IN2015DN01786A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US75003605P 2005-12-13 2005-12-13
US80029406P 2006-05-15 2006-05-15
US11/637,520 US8076303B2 (en) 2005-12-13 2006-12-12 Nucleotide and oligonucleotide prodrugs
PCT/US2006/047617 WO2007070598A2 (en) 2005-12-13 2006-12-13 Nucleotide and oligonucleotide prodrugs

Publications (1)

Publication Number Publication Date
IN2015DN01786A true IN2015DN01786A (es) 2015-07-10

Family

ID=38194676

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1786DEN2015 IN2015DN01786A (es) 2005-12-13 2006-12-13

Country Status (17)

Country Link
US (6) US8076303B2 (es)
EP (3) EP1968612B1 (es)
JP (1) JP5044854B2 (es)
KR (2) KR101123534B1 (es)
CN (2) CN101437397B (es)
CY (2) CY1117576T1 (es)
DK (2) DK1968612T3 (es)
ES (2) ES2573928T3 (es)
HR (1) HRP20160531T1 (es)
HU (2) HUE029190T2 (es)
IN (1) IN2015DN01786A (es)
LT (1) LT3090748T (es)
PL (2) PL3090748T3 (es)
PT (1) PT3090748T (es)
RS (1) RS54867B1 (es)
SI (2) SI3090748T1 (es)
WO (1) WO2007070598A2 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7589075B2 (en) * 2001-01-16 2009-09-15 Can-Fite Biopharma Ltd. Use of an adenosine A3 receptor agonist for inhibition of viral replication
US8076303B2 (en) * 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
KR101927905B1 (ko) 2008-04-03 2018-12-11 스프링 뱅크 파마슈티칼스, 인크. 바이러스 감염증을 치료하기 위한 조성물 및 방법
EP2346883B1 (en) * 2008-09-23 2016-03-23 Scott G. Petersen Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference
BRPI0923225A2 (pt) 2008-12-02 2016-10-04 Chiralgen Ltd metodo para sintese de acidos nucleicos modificados no atomo de fosforo
CN102307889A (zh) * 2008-12-23 2012-01-04 集润德斯股份公司 硫化剂及其用于寡核苷酸合成的用途
KR101885383B1 (ko) * 2009-07-06 2018-08-03 웨이브 라이프 사이언시스 리미티드 신규한 핵산 프로드러그 및 그의 사용 방법
AU2015255202B2 (en) * 2009-07-06 2017-07-27 Wave Life Sciences Ltd. Novel nucleic acid prodrugs and methods of use thereof
CN101659612B (zh) * 2009-09-24 2013-01-09 华润赛科药业有限责任公司 一种选择性酯化的方法
CN107973833A (zh) * 2010-08-30 2018-05-01 斯普林银行医药公司 作为治疗剂的寡核苷酸类似物的设计
JP5868324B2 (ja) 2010-09-24 2016-02-24 株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ 不斉補助基
CN103796657B (zh) 2011-07-19 2017-07-11 波涛生命科学有限公司 合成官能化核酸的方法
KR101327026B1 (ko) 2011-11-29 2013-11-13 현대자동차주식회사 운전자 보호장치
EP2873674B1 (en) 2012-07-13 2020-05-06 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
SG11201500239VA (en) 2012-07-13 2015-03-30 Wave Life Sciences Japan Asymmetric auxiliary group
EP4219516A3 (en) 2012-07-13 2024-01-10 Wave Life Sciences Ltd. Chiral control
KR20150119924A (ko) * 2013-02-18 2015-10-26 스프링 뱅크 파마슈티칼스, 인크. 백신 애쥬번트 및 치료제로서의 짧은 올리고뉴클레오티드의 설계
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
WO2015108047A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
KR102423317B1 (ko) 2014-01-16 2022-07-22 웨이브 라이프 사이언시스 리미티드 키랄 디자인
GB201403697D0 (en) * 2014-03-03 2014-04-16 Link Technologies Ltd Compounds and methods of use
CN115990171A (zh) * 2014-09-28 2023-04-21 华辉安健（北京）生物科技有限公司 聚合胆汁酸衍生物抑制乙型肝炎病毒和丁型肝炎病毒和ntcp运输
US20190046552A1 (en) * 2015-04-07 2019-02-14 Spring Bank Pharmaceuticals, Inc. Compositions and methods for the treatment of hcv infection
AU2016287580A1 (en) * 2015-07-02 2018-02-15 Spring Bank Pharmaceuticals, Inc. Compositions and methods for the treatment of viral infection
US20190070212A1 (en) * 2016-03-11 2019-03-07 Spring Bank Pharmaceuticals, Inc. Compounds and compositions for the treatment of infections
CN109715202A (zh) * 2016-07-15 2019-05-03 斯必乐维生物科学公司 用于治疗疾病的化合物、组合物和方法
JOP20170192A1 (ar) * 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
US20200055883A1 (en) 2017-02-17 2020-02-20 Eisai R&D Management Co., Ltd. Cyclic di-nucleotides derivative for the treatment of cancer
AR113224A1 (es) 2017-04-28 2020-02-19 Novartis Ag Conjugados de anticuerpo que comprenden un agonista de sting
WO2019051489A1 (en) * 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
US11584774B2 (en) 2017-09-11 2023-02-21 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
CN110467646A (zh) * 2018-05-09 2019-11-19 博瑞生物医药（苏州）股份有限公司 双核苷酸前体药物
CN110467647B (zh) * 2018-05-09 2022-08-30 博瑞生物医药（苏州）股份有限公司 双核苷酸前体药物的制备方法
WO2019219070A1 (zh) * 2018-05-18 2019-11-21 正大天晴药业集团股份有限公司 氘代的低聚核苷酸及前体药物
CN112512531B (zh) 2018-06-01 2024-04-09 卫材R&D管理有限公司 用于膀胱癌的治疗的方法
FR3082434B1 (fr) 2018-06-14 2021-04-30 Cairdac Implant cardiaque autonome de type "capsule leadless", comprenant un recuperateur d'energie a lame piezoelectrique
CA3099904A1 (en) 2018-08-16 2020-02-20 Eisai R&D Management Co., Ltd. Salts of compounds and crystals thereof
CN113348181A (zh) 2018-10-31 2021-09-03 诺华股份有限公司 包含sting激动剂的dc-sign抗体缀合物
WO2020089815A1 (en) 2018-10-31 2020-05-07 Novartis Ag Antibody conjugates comprising sting agonist
CN113164506B (zh) * 2018-12-06 2023-12-08 正大天晴药业集团股份有限公司 二核苷酸化合物及其前体药物
CN111484541B (zh) * 2019-01-25 2023-06-02 博瑞生物医药（苏州）股份有限公司 双核苷酸前体药物及其制备方法
CN111484540B (zh) * 2019-01-25 2023-09-08 博瑞生物医药（苏州）股份有限公司 含双核苷酸结构的化合物
JP7421280B2 (ja) 2019-07-30 2024-01-24 三和シヤッター工業株式会社 建具

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US688183A (en) 1900-12-17 1901-12-03 Carl C Lantz Adjusting-clip for garment-supporters.
DE2817041A1 (de) 1978-04-19 1979-10-31 Reich Maschf Gmbh Karl Verfahren und vorrichtung zum aufteilen von platten
CS264222B1 (en) * 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
CA2078444A1 (en) 1990-04-18 1991-10-19 Thomas P. Demuth, Jr. Antimicrobial quinolonyl lactams
US5444063A (en) 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5432165A (en) 1992-04-06 1995-07-11 Oclassen Pharmaceuticals, Inc. Methods for the treatment of infection caused by Hepatitis B virus (HBV)
FR2705099B1 (fr) * 1993-05-12 1995-08-04 Centre Nat Rech Scient Oligonucléotides phosphorothioates triesters et procédé de préparation.
US5955591A (en) 1993-05-12 1999-09-21 Imbach; Jean-Louis Phosphotriester oligonucleotides, amidites and method of preparation
FR2709754B1 (fr) * 1993-09-10 1995-12-01 Centre Nat Rech Scient Composés 2' ou 3'-déoxy- et 2', 3'-didéoxy-beta-L-pentofuranonucléosides, procédé de préparation et application thérapeutique, notamment anti-virale.
US5587362A (en) 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
US5581639A (en) 1995-05-04 1996-12-03 National Research Council Of Canada Raman-nath diffraction grating
AU4156197A (en) 1996-08-21 1998-03-06 Hybridon, Inc. Oligonucleotide prodrugs
AU4988697A (en) 1996-10-24 1998-05-15 Vion Pharmaceuticals, Inc. Monophosphate prodrugs of beta-l-fd4c and beta-l-fddc as potent antiviral agents
US6444652B1 (en) 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
ES2579903T3 (es) 1998-08-10 2016-08-17 Centre National De La Recherche Scientifique (Cnrs) Beta-L-2'-desoxi-nucleósidos para el tratamiento de la hepatitis B
CA2599597A1 (en) 1998-08-10 2000-02-24 Idenix (Cayman) Limited .beta.-l-2'-deoxy-nucleosides for the treatment of hepatitis b
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
KR100767432B1 (ko) 2000-07-21 2007-10-17 길리애드 사이언시즈, 인코포레이티드 포스포네이트 뉴클레오티드 유사체의 전구 약물과 그것의 선택 및 제조 방법
JP2005525991A (ja) * 2001-05-16 2005-09-02 マイジェニックス インコーポレイテッド 核酸ベースの化合物およびその使用方法
US8076303B2 (en) * 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
CN101146337B (zh) 2006-09-15 2011-04-20 华为技术有限公司 新接入节点随机接入的方法及其系统
KR101927905B1 (ko) * 2008-04-03 2018-12-11 스프링 뱅크 파마슈티칼스, 인크. 바이러스 감염증을 치료하기 위한 조성물 및 방법

Also Published As

Publication number Publication date
EP1968612A2 (en) 2008-09-17
EP1968612A4 (en) 2013-01-09
KR20080072084A (ko) 2008-08-05
US10047114B2 (en) 2018-08-14
US20140323554A1 (en) 2014-10-30
US20160060287A1 (en) 2016-03-03
US10344046B2 (en) 2019-07-09
PL1968612T3 (pl) 2016-11-30
RS54867B1 (sr) 2016-10-31
ES2573928T3 (es) 2016-06-13
WO2007070598A9 (en) 2007-11-08
PT3090748T (pt) 2019-06-04
HUE029190T2 (en) 2017-02-28
DK3090748T3 (da) 2019-05-27
US20070149462A1 (en) 2007-06-28
SI3090748T1 (sl) 2019-09-30
KR101248873B1 (ko) 2013-04-02
US8691787B2 (en) 2014-04-08
US8076303B2 (en) 2011-12-13
SI1968612T1 (sl) 2016-10-28
EP3090748B1 (en) 2019-02-20
ES2729657T3 (es) 2019-11-05
HRP20160531T1 (hr) 2016-08-12
JP5044854B2 (ja) 2012-10-10
HUE044034T2 (hu) 2019-09-30
KR20110125677A (ko) 2011-11-21
EP3090748A1 (en) 2016-11-09
CY1121639T1 (el) 2020-07-31
US20200087338A1 (en) 2020-03-19
JP2009519345A (ja) 2009-05-14
PL3090748T3 (pl) 2020-03-31
US20120264709A1 (en) 2012-10-18
WO2007070598A3 (en) 2008-10-30
WO2007070598A2 (en) 2007-06-21
US20180273574A1 (en) 2018-09-27
CN102796155A (zh) 2012-11-28
EP3553072A1 (en) 2019-10-16
EP1968612B1 (en) 2016-03-09
WO2007070598A8 (en) 2008-12-31
CN101437397A (zh) 2009-05-20
CY1117576T1 (el) 2017-04-26
DK1968612T3 (en) 2017-05-22
CN102796155B (zh) 2015-08-26
LT3090748T (lt) 2019-08-26
CN101437397B (zh) 2012-09-05
KR101123534B1 (ko) 2012-03-13

Similar Documents

Publication Publication Date Title
IN2015DN01786A (es)
EA201300860A1 (ru) Кристаллические трипептидные ингибиторы эпоксикетон-протеазы
MX2009003727A (es) Acidos y esteres boronicos como inhibidores de amida hidrolasa de acido graso.
MX2009008439A (es) Nuevos inhibidores de la replicacion del virus de hepatitis c.
WO2009026176A3 (en) Antiinfective flavononol compounds and methods of use thereof
ATE511835T1 (de) Biophosphonate zur behandlung von endometriose
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
TW200806299A (en) Treatment of pain
RU2010144637A (ru) Замещенные гамма-лактамы в качестве терапевтических агентов
TN2009000481A1 (en) Novel peptide inhibitors of hepatitis c virus replication
ATE537175T1 (de) Neue piperazino-dihydrothienopyrimidin-derivate
IL198901A0 (en) Pyrimidine derivatives and multiple myeloma
MX2013014938A (es) Compuestos para el tratamiento de la adiccion.
EP2671891A3 (en) Ang-2 inhibition to treat multiple sclerosis
MY150903A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
MY162022A (en) Chemical compounds 637: pyridopyrimidinediones as pde4 inhibitors
TW200639159A (en) Treatment of pain
MX2009009238A (es) Nuevos inhibidores de fosfodiesterasa.
PL2099769T3 (pl) Związki 6-okso-1,6-dihydropirymidyn-2-ylowe do leczenia chorób proliferacyjnych
SE0501903L (sv) Borföreningar användbara vid BNCT
TNSN08506A1 (en) Substituted carboxamides
MX2011012068A (es) Nucleosidos 2'-fluoro arabino y su utilizaicon.
MY156278A (en) Disubstituted [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones
WO2007149543A3 (en) Scar treatment using protein phosphatase inhibitors
WO2007047893A3 (en) Use of dasatinib for the treatment of bone metastasis